Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Targeting VE-PTP phosphatase protects the kidney from diabetic injury.

Carota IA, Kenig-Kozlovsky Y, Onay T, Scott R, Thomson BR, Souma T, Bartlett CS, Li Y, Procissi D, Ramirez V, Yamaguchi S, Tarjus A, Tanna CE, Li C, Eremina V, Vestweber D, Oladipupo SS, Breyer MD, Quaggin SE.

J Exp Med. 2019 Apr 1;216(4):936-949. doi: 10.1084/jem.20180009. Epub 2019 Mar 18.

2.

Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.

Zhang M, Srichai MB, Zhao M, Chen J, Davis LS, Wu G, Breyer MD, Hao CM.

Int J Med Sci. 2019 Jan 1;16(1):180-188. doi: 10.7150/ijms.27719. eCollection 2019.

3.

Pathological and Transcriptome Changes in the ReninAAV db/ db uNx Model of Advanced Diabetic Kidney Disease Exhibit Features of Human Disease.

Harlan SM, Heinz-Taheny KM, Overstreet JM, Breyer MD, Harris RC, Heuer JG.

Toxicol Pathol. 2018 Dec;46(8):991-998. doi: 10.1177/0192623318804986. Epub 2018 Nov 5.

PMID:
30392455
4.

Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, Duffin KL, Breyer MD, Pullen N, Bonventre JV, Krolewski AS.

Kidney Int. 2018 May;93(5):1198-1206. doi: 10.1016/j.kint.2017.11.024. Epub 2018 Feb 2.

5.

Novel avenues for drug discovery in diabetic kidney disease.

Breyer MD, Kretzler M.

Expert Opin Drug Discov. 2018 Jan;13(1):65-74. doi: 10.1080/17460441.2018.1398731. Epub 2017 Nov 16. Review.

PMID:
29145743
6.

Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.

Harlan SM, Heinz-Taheny KM, Sullivan JM, Wei T, Baker HE, Jaqua DL, Qi Z, Cramer MS, Shiyanova TL, Breyer MD, Heuer JG.

J Am Soc Nephrol. 2018 Feb;29(2):477-491. doi: 10.1681/ASN.2017040385. Epub 2017 Oct 23.

7.

A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.

Fujihara CK, Kowala MC, Breyer MD, Sena CR, Rodrigues MV, Arias SCA, Fanelli C, Malheiros DM, Jadhav PK, Montrose-Rafizadeh C, Krieger JE, Zatz R.

Sci Rep. 2017 Aug 11;7(1):7899. doi: 10.1038/s41598-017-08383-2.

8.

Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.

Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, Galecki AT, Duffin KL, Pullen N, Breyer MD, Bonventre JV, Warram JH, Krolewski AS.

Kidney Int. 2017 Jul;92(1):258-266. doi: 10.1016/j.kint.2017.02.010. Epub 2017 Apr 7.

9.

Role of TGF-alpha in the progression of diabetic kidney disease.

Heuer JG, Harlan SM, Yang DD, Jaqua DL, Boyles JS, Wilson JM, Heinz-Taheny KM, Sullivan JM, Wei T, Qian HR, Witcher DR, Breyer MD.

Am J Physiol Renal Physiol. 2017 Jun 1;312(6):F951-F962. doi: 10.1152/ajprenal.00443.2016. Epub 2017 Mar 1.

10.

Developing Treatments for Chronic Kidney Disease in the 21st Century.

Breyer MD, Susztak K.

Semin Nephrol. 2016 Nov;36(6):436-447. doi: 10.1016/j.semnephrol.2016.08.001. Review.

11.

The next generation of therapeutics for chronic kidney disease.

Breyer MD, Susztak K.

Nat Rev Drug Discov. 2016 Aug;15(8):568-88. doi: 10.1038/nrd.2016.67. Epub 2016 May 27. Review.

12.

Overcoming Barriers in Kidney Health-Forging a Platform for Innovation.

Linde PG, Archdeacon P, Breyer MD, Ibrahim T, Inrig JK, Kewalramani R, Lee CC, Neuland CY, Roy-Chaudhury P, Sloand JA, Meyer R, Smith KA, Snook J, West M, Falk RJ.

J Am Soc Nephrol. 2016 Jul;27(7):1902-10. doi: 10.1681/ASN.2015090976. Epub 2016 Apr 28.

13.

Prostaglandin-dependent modulation of dopaminergic neurotransmission elicits inflammation-induced aversion in mice.

Fritz M, Klawonn AM, Nilsson A, Singh AK, Zajdel J, Wilhelms DB, Lazarus M, Löfberg A, Jaarola M, Kugelberg UÖ, Billiar TR, Hackam DJ, Sodhi CP, Breyer MD, Jakobsson J, Schwaninger M, Schütz G, Parkitna JR, Saper CB, Blomqvist A, Engblom D.

J Clin Invest. 2016 Feb;126(2):695-705.

14.

From bench to patient: model systems in drug discovery.

Breyer MD, Look AT, Cifra A.

Dis Model Mech. 2015 Oct 1;8(10):1171-4. doi: 10.1242/dmm.023036.

15.

Viral transduction of renin rapidly establishes persistent hypertension in diverse murine strains.

Harlan SM, Ostroski RA, Coskun T, Yantis LD, Breyer MD, Heuer JG.

Am J Physiol Regul Integr Comp Physiol. 2015 Sep;309(5):R467-74. doi: 10.1152/ajpregu.00106.2015. Epub 2015 Jun 24.

16.

Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study.

Cid Ruzafa J, Paczkowski R, Boye KS, Di Tanna GL, Sheetz MJ, Donaldson R, Breyer MD, Neasham D, Voelker JR.

Int J Clin Pract. 2015 Aug;69(8):871-82. doi: 10.1111/ijcp.12640. Epub 2015 May 25.

PMID:
26011029
17.

A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease.

Agarwal R, Duffin KL, Laska DA, Voelker JR, Breyer MD, Mitchell PG.

Nephrol Dial Transplant. 2014 Dec;29(12):2293-302. doi: 10.1093/ndt/gfu255. Epub 2014 Aug 1.

PMID:
25085239
18.

Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-α and epiregulin.

Beidler CB, Petrovan RJ, Conner EM, Boyles JS, Yang DD, Harlan SM, Chu S, Ellis B, Datta-Mannan A, Johnson RL, Stauber A, Witcher DR, Breyer MD, Heuer JG.

J Pharmacol Exp Ther. 2014 May;349(2):330-43. doi: 10.1124/jpet.113.210765. Epub 2014 Feb 11.

PMID:
24518034
19.

Improving productivity of modern-day drug discovery.

Breyer MD.

Expert Opin Drug Discov. 2014 Feb;9(2):115-8. doi: 10.1517/17460441.2014.870150. Epub 2013 Dec 12.

PMID:
24328737
20.

Generation of a tenascin-C-CreER2 knockin mouse line for conditional DNA recombination in renal medullary interstitial cells.

He W, Xie Q, Wang Y, Chen J, Zhao M, Davis LS, Breyer MD, Gu G, Hao CM.

PLoS One. 2013 Nov 11;8(11):e79839. doi: 10.1371/journal.pone.0079839. eCollection 2013.

21.

Increased dietary sodium induces COX2 expression by activating NFκB in renal medullary interstitial cells.

He W, Zhang M, Zhao M, Davis LS, Blackwell TS, Yull F, Breyer MD, Hao CM.

Pflugers Arch. 2014 Feb;466(2):357-367. doi: 10.1007/s00424-013-1328-7. Epub 2013 Jul 31.

22.

Diabetic nephropathy: a national dialogue.

Breyer MD, Coffman TM, Flessner MF, Fried LF, Harris RC, Ketchum CJ, Kretzler M, Nelson RG, Sedor JR, Susztak K; Kidney Research National Dialogue (KRND).

Clin J Am Soc Nephrol. 2013 Sep;8(9):1603-5. doi: 10.2215/CJN.03640413. Epub 2013 Jun 20.

23.

Circulating αKlotho influences phosphate handling by controlling FGF23 production.

Smith RC, O'Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, Roberts JL, Cass TA, Saha J, Broderick C, Ma YL, Zeng QQ, Kharitonenkov A, Wilson JM, Guo Q, Sun H, Allen MR, Burr DB, Breyer MD, White KE.

J Clin Invest. 2012 Dec;122(12):4710-5. doi: 10.1172/JCI64986. Epub 2012 Nov 26.

24.

Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.

Chen L, Miao Y, Zhang Y, Dou D, Liu L, Tian X, Yang G, Pu D, Zhang X, Kang J, Gao Y, Wang S, Breyer MD, Wang N, Zhu Y, Huang Y, Breyer RM, Guan Y.

Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):3024-32. doi: 10.1161/ATVBAHA.112.254052. Epub 2012 Oct 11.

25.

Drug discovery for diabetic nephropathy: trying the leap from mouse to man.

Breyer MD.

Semin Nephrol. 2012 Sep;32(5):445-51. doi: 10.1016/j.semnephrol.2012.07.007.

PMID:
23062985
26.

SOD1, but not SOD3, deficiency accelerates diabetic renal injury in C57BL/6-Ins2(Akita) diabetic mice.

Fujita H, Fujishima H, Takahashi K, Sato T, Shimizu T, Morii T, Shimizu T, Shirasawa T, Qi Z, Breyer MD, Harris RC, Yamada Y, Takahashi T.

Metabolism. 2012 Dec;61(12):1714-24. doi: 10.1016/j.metabol.2012.05.005. Epub 2012 May 25.

27.

Generation of a conditional allele for the mouse endothelial nitric oxide synthase gene.

Jiang R, Wang S, Takahashi K, Fujita H, Fruci CR, Breyer MD, Harris RC, Takahashi T.

Genesis. 2012 Sep;50(9):685-92. doi: 10.1002/dvg.22026. Epub 2012 May 10.

28.

Prostaglandin E2-mediated attenuation of mesocortical dopaminergic pathway is critical for susceptibility to repeated social defeat stress in mice.

Tanaka K, Furuyashiki T, Kitaoka S, Senzai Y, Imoto Y, Segi-Nishida E, Deguchi Y, Breyer RM, Breyer MD, Narumiya S.

J Neurosci. 2012 Mar 21;32(12):4319-29. doi: 10.1523/JNEUROSCI.5952-11.2012.

29.

Translating experimental diabetic nephropathy studies from mice to men.

Breyer MD.

Contrib Nephrol. 2011;170:156-164. doi: 10.1159/000325651. Epub 2011 Jun 9.

PMID:
21659768
30.

EP1(-/-) mice have enhanced osteoblast differentiation and accelerated fracture repair.

Zhang M, Ho HC, Sheu TJ, Breyer MD, Flick LM, Jonason JH, Awad HA, Schwarz EM, O'Keefe RJ.

J Bone Miner Res. 2011 Apr;26(4):792-802. doi: 10.1002/jbmr.272.

31.

Enhanced pressor response to acute Ang II infusion in mice lacking membrane-associated prostaglandin E2 synthase-1.

Zhang DJ, Chen LH, Zhang YH, Yang GR, Dou D, Gao YS, Zhang XY, Kong XM, Zhao P, Pu D, Wei MF, Breyer MD, Guan YF.

Acta Pharmacol Sin. 2010 Oct;31(10):1284-92. doi: 10.1038/aps.2010.99. Epub 2010 Sep 27.

32.

Progress in progression?

Breyer MD.

J Am Soc Nephrol. 2010 Sep;21(9):1414-6. doi: 10.1681/ASN.2010070744. Epub 2010 Aug 12. No abstract available.

33.

A maladaptive role for EP4 receptors in podocytes.

Stitt-Cavanagh EM, Faour WH, Takami K, Carter A, Vanderhyden B, Guan Y, Schneider A, Breyer MD, Kennedy CR.

J Am Soc Nephrol. 2010 Oct;21(10):1678-90. doi: 10.1681/ASN.2009121234. Epub 2010 Jul 29.

34.

Sirt1 activation protects the mouse renal medulla from oxidative injury.

He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, Yang HC, Fogo AB, Zent R, Harris RC, Breyer MD, Hao CM.

J Clin Invest. 2010 Apr;120(4):1056-68. doi: 10.1172/JCI41563. Epub 2010 Mar 24.

35.

Osteopontin in diabetic nephropathy: signpost or road?

Heuer JG, Breyer MD.

Kidney Int. 2010 Apr;77(7):565-6. doi: 10.1038/ki.2009.515.

36.

Better nephrology for mice--and man.

Breyer MD, Qi Z.

Kidney Int. 2010 Mar;77(6):487-9. doi: 10.1038/ki.2009.544.

37.

Mouse models of diabetic nephropathy.

Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T; Animal Models of Diabetic Complications Consortium.

J Am Soc Nephrol. 2009 Dec;20(12):2503-12. doi: 10.1681/ASN.2009070721. Epub 2009 Sep 3. Review.

38.

Reduction of renal superoxide dismutase in progressive diabetic nephropathy.

Fujita H, Fujishima H, Chida S, Takahashi K, Qi Z, Kanetsuna Y, Breyer MD, Harris RC, Yamada Y, Takahashi T.

J Am Soc Nephrol. 2009 Jun;20(6):1303-13. doi: 10.1681/ASN.2008080844. Epub 2009 May 21.

39.

Effects of global or targeted deletion of the EP4 receptor on the response of osteoblasts to prostaglandin in vitro and on bone histomorphometry in aged mice.

Gao Q, Zhan P, Alander CB, Kream BE, Hao C, Breyer MD, Pilbeam CC, Raisz LG.

Bone. 2009 Jul;45(1):98-103. doi: 10.1016/j.bone.2009.03.667. Epub 2009 Apr 1.

PMID:
19344793
40.

Measurement of glomerular filtration rate in conscious mice.

Qi Z, Breyer MD.

Methods Mol Biol. 2009;466:61-72. doi: 10.1007/978-1-59745-352-3_5.

PMID:
19148601
41.

Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis.

Babaev VR, Chew JD, Ding L, Davis S, Breyer MD, Breyer RM, Oates JA, Fazio S, Linton MF.

Cell Metab. 2008 Dec;8(6):492-501. doi: 10.1016/j.cmet.2008.09.005.

42.

Single amino acid substitution in aquaporin 11 causes renal failure.

Tchekneva EE, Khuchua Z, Davis LS, Kadkina V, Dunn SR, Bachman S, Ishibashi K, Rinchik EM, Harris RC, Dikov MM, Breyer MD.

J Am Soc Nephrol. 2008 Oct;19(10):1955-64. doi: 10.1681/ASN.2008030296. Epub 2008 Aug 13.

43.

Stacking the deck for drug discovery in diabetic nephropathy: in search of an animal model.

Breyer MD.

J Am Soc Nephrol. 2008 Sep;19(9):1623-4. doi: 10.1681/ASN.2008070705. Epub 2008 Aug 6. No abstract available.

44.

Markers of glycemic control in the mouse: comparisons of 6-h- and overnight-fasted blood glucoses to Hb A1c.

Han BG, Hao CM, Tchekneva EE, Wang YY, Lee CA, Ebrahim B, Harris RC, Kern TS, Wasserman DH, Breyer MD, Qi Z.

Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E981-6. doi: 10.1152/ajpendo.90283.2008. Epub 2008 Jul 29.

45.

Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats.

Zhou Y, Zhang X, Chen L, Wu J, Dang H, Wei M, Fan Y, Zhang Y, Zhu Y, Wang N, Breyer MD, Guan Y.

Am J Physiol Renal Physiol. 2008 Sep;295(3):F662-71. doi: 10.1152/ajprenal.00046.2008. Epub 2008 Jul 9.

46.

Apoptosis of the thick ascending limb results in acute kidney injury.

Srichai MB, Hao C, Davis L, Golovin A, Zhao M, Moeckel G, Dunn S, Bulus N, Harris RC, Zent R, Breyer MD.

J Am Soc Nephrol. 2008 Aug;19(8):1538-46. doi: 10.1681/ASN.2007101101. Epub 2008 May 21.

47.

Examining diabetic nephropathy through the lens of mouse genetics.

Breyer MD, Tchekneva E, Qi Z, Takahashi T, Fogo AB, Harris RC.

Curr Diab Rep. 2007 Dec;7(6):459-66. Review.

PMID:
18255011
48.

Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo.

Macias-Perez IM, Zent R, Carmosino M, Breyer MD, Breyer RM, Pozzi A.

J Biol Chem. 2008 May 2;283(18):12538-45. doi: 10.1074/jbc.M800105200. Epub 2008 Jan 29.

49.

Insight into the genetics of diabetic nephropathy through the study of mice.

Breyer MD, Qi Z, Tchekneva EE, Harris RC.

Curr Opin Nephrol Hypertens. 2008 Jan;17(1):82-6. Review.

PMID:
18090675
50.

Physiological regulation of prostaglandins in the kidney.

Hao CM, Breyer MD.

Annu Rev Physiol. 2008;70:357-77. Review.

PMID:
17988207

Supplemental Content

Loading ...
Support Center